Table 1 Baseline tumour, patient and treatment characteristics for all patients (n = 26)
Characteristic | All patients (n = 26) |
|---|---|
Age at registration—median (min, max) | 68.7 (43.5, 82.9) |
Gender—n(%) | |
Male | 13 (50.0) |
Female | 13 (50.0) |
Primary lung location—n(%) | |
Left upper lobe | 2 (7.7) |
Left lower lobe | 3 (11.5) |
Right upper lobe | 13 (50.0) |
Right middle lobe | 4 (15.4) |
Right lower lobe | 4 (15.4) |
Pre-treatment size (cm)—mean ± SD | 2.8 ± 1.1 |
T stage—n(%) | |
T1 | 20 (76.9) |
T2 | 6 (23.1) |
Histology—n(%) | |
Adenocarcinoma | 16 (61.5) |
Squamous | 9 (34.6) |
NSCLC NOS | 1 (3.9) |
Pre-treatment FEV1—mean ± SD | 73.7 ± 16.4 |
Post-treatment FEV1—mean ± SD | 75.1 ± 20.2 |
Change FEV1—mean ± SD | 0.1 ± 13.5 |
Dose fractionation—n(%) | |
54 Gy in 3 fractions | 5 (19.2) |
55 Gy in 5 fractions | 15 (57.7) |
60 Gy in 8 fractions | 6 (23.1) |
Surgery—n(%) | 26 (100) |
Surgery type—n(%) | |
Lobectomy | 18 (69.2) |
Wedge resection | 8 (30.8) |
Surgical approach—n(%) | |
VATS | 21 (80.8) |
VATS converted to open | 3 (11.5) |
Open | 2 (7.7) |